A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Asian Subjects With T2DM and Inadequate Glycemic Control on Metformin and Saxagliptin (DS Navigation)

This is a 24-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled,
parallel group, phase 3 study designed to evaluate if the safety and efficacy of
dapagliflozin 5 mg or 10 mg added to saxagliptin 5 mg plus metformin is superior to placebo
added to saxagliptin 5 mg plus metformin in reducing hemoglobin A1c (HbA1c).